Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ekso Bionics Holdings Inc. filings document material-event disclosures, financing arrangements, governance actions, capital-structure changes, and operating results for an exoskeleton technology issuer. The company’s Form 8-K disclosures include financial results, material agreements, shareholder voting matters, and security-structure information tied to preferred stock, warrants, and other corporate actions.
Regulatory filings also cover a private placement of Series B Convertible Preferred Stock and warrants, a secured term loan involving subsidiary Ekso Bionics, Inc. as guarantor, equity awards under the company’s Amended and Restated 2014 Equity Incentive Plan, and governance matters associated with the company’s corporate transition.
Mink Brook reporting persons report beneficial ownership of 190,596 shares (5.4%) of Ekso Bionics common stock. As of the close of business on April 8, 2026, Mink Brook Partners LP held 190,596 shares. The filing states shared voting and shared dispositive power among Mink Brook Capital GP LLC, Mink Brook Asset Management LLC, and William Mueller. The percentage is calculated using 3,563,381 shares outstanding as of February 23, 2026 disclosed in the company’s Form 10-K; the filers include a disclaimer of beneficial ownership except to the extent of pecuniary interest.
Ekso Bionics Holdings, Inc. is notifying stockholders that holders of approximately 50.4% of voting power approved, by written consent, a business combination under which Applied Digital Cloud Corporation (“Cloud”) will be contributed to Ekso in exchange for 138,216,820 newly issued shares, making Cloud a wholly owned subsidiary.
Immediately prior to closing the Transactions, Applied Parent expects to subscribe for at least $15.0 million of common stock. Upon closing (assuming specified conversions, vesting and a $11.81 assumed PIPE price), legacy Ekso holders would hold ~3%, Contributor ~96%, and Applied Parent ~1% of the combined company, which will be renamed ChronoScale Corporation.
Ekso Bionics Holdings, Inc. is notifying holders that Principal Stockholders holding ~50.4% approved by written consent a combination that will contribute Applied Digital Cloud Corporation into Ekso in exchange for 138,216,820 newly issued shares, amend the charter to increase authorized common shares to 290,000,000, adopt the ChronoScale 2026 equity plan and permit a private $15.0M Applied Parent equity purchase. Immediately after closing (assuming full conversion and an assumed $11.81 share price) Contributor would hold ~96% of the combined company, legacy holders ~3% and Applied Parent ~1%. The Company expects to file a Nasdaq listing application for the renamed ChronoScale Corporation. Closing is conditioned on customary regulatory, listing and cash requirements and will not occur until 20 calendar days after mailing this statement.
Ekso Bionics Holdings, Inc. notified holders that Principal Stockholders holding approximately 50.4% approved by written consent a transaction to acquire Applied Digital Cloud Corporation’s business in exchange for 138,216,820 newly issued shares, amend its articles to increase authorized common stock and change its name to ChronoScale Corporation. The closing is subject to customary conditions, including Nasdaq listing approval and an Applied Parent Equity Financing expected to raise at least $15.0 million. Following closing, pro forma ownership (based on shares outstanding as of February 20, 2026) is expected to be ~96% Contributor, ~1% Applied Parent and ~3% legacy holders, assuming certain conversions, vesting and an illustrative price of $11.81 per share.
Ekso Bionics Holdings Chief Operating Officer Jason C. Jones increased his ownership through a small share acquisition tied to the company’s retirement plan. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share in an open-market purchase recorded under his 401(k) account, as part of the issuer’s 401(k) contribution matching program.
After this transaction, he indirectly holds 4,449 shares through the 401(k) and directly holds 25,621 shares of common stock. The share amounts disclosed have been adjusted to reflect a prior 1-for-15 reverse stock split.
Ekso Bionics Holdings, Inc. Chief Financial Officer Jerome Wong reported an open-market purchase of common stock through a 401(k) plan. He acquired 1,308 shares on March 16, 2026 at $11.85 per share, held indirectly via a 401(k) account under the company’s matching contribution program.
Following this transaction, he indirectly held 4,184 shares through the 401(k) and directly held 24,771 shares of common stock. A prior 1-for-15 reverse stock split effective on June 2, 2025 is reflected in the reported share amounts.
Ekso Bionics Holdings, Inc. announced that holders of approximately 50.4% of its voting stock approved, by written consent, a business combination under which Applied Digital affiliates will contribute Applied Digital Cloud Corporation ("Cloud") to Ekso in exchange for 138,216,820 newly issued shares of Common Stock.
The transaction contemplates an immediate $15.0M private subscription by Applied Parent, an amendment increasing authorized Common Stock to 290,000,000 shares, and a name change to ChronoScale Corporation. Post-Closing ownership is expected to be roughly 96% Contributor, 1% Applied Parent and 3% legacy Ekso holders (based on shares outstanding as of February 20, 2026), subject to closing conditions, Nasdaq approval, and other customary requirements.
Ekso Bionics Holdings, Inc. Schedule 13G filing discloses that Cedar Holdings Mgmt LLC beneficially owns 210,000 shares of Common Stock, representing 5.89% of the class based on February 20, 2026 outstanding shares of 3,563,381. The filing states Cedar has shared voting and dispositive power over the shares and that Keith Kosow may be deemed to beneficially own those shares by virtue of his role; Mr. Kosow does not directly own the Shares. The ownership percentages are tied to the issuer's Form 10-K disclosure of shares outstanding as of February 20, 2026.
Ekso Bionics Holdings, Inc. files its annual report describing a medical exoskeleton and rehabilitation technology business focused on Enterprise Health and Personal Health markets. The company details its product portfolio, CMS-backed reimbursement for the Ekso Indego Personal device, extensive regulatory requirements, and a sizable global patent estate.
A proposed business combination would contribute Applied Digital’s cloud computing subsidiary in exchange for 138,216,820 new Ekso shares, leaving Applied’s affiliate with roughly 97% of the combined company before other related issuances. The filing warns that if this transaction fails, Ekso expects limited liquidity, potential need for highly dilutive financing, and possible restructuring or wind-down.
Ekso Bionics Holdings, Inc. insider Daniel Asher, a more than ten percent owner, reported an indirect open-market purchase of common stock. On February 19, 2026, DBA Trading, LLC, an entity beneficially owned by Asher, bought 15,540 shares of common stock at an average price of $12.3013 per share. After this trade, DBA Trading, LLC held 270,432 common shares indirectly for Asher. Asher is also shown as indirectly holding 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, and directly holding 165,000 common shares, reflecting a significant overall stake in Ekso Bionics.